Consensus Statement: Cardiovascular Safety Profile of Triptans (5‐HT1B/1D Agonists) in the Acute Treatment of Migraine
Tóm tắt
Background.—Health care providers frequently cite concerns about cardiovascular safety of the triptans as a barrier to their use. In 2002, the American Headache Society convened the Triptan Cardiovascular Safety Expert Panel to evaluate the evidence on triptan‐associated cardiovascular risk and to formulate consensus recommendations for making informed decisions for their use in patients with migraine.
Objective.—To summarize the evidence reviewed by the Triptan Cardiovascular Safety Expert Panel and their recommendations for the use of triptans in clinical practice.
Participants.—The Triptan Cardiovascular Safety Expert Panel was composed of a multidisciplinary group of experts in neurology, primary care, cardiology, pharmacology, women's health, and epidemiology.
Evidence and Consensus Process.—An exhaustive search of the relevant published literature was reviewed by each panel member in preparation for an open roundtable meeting. Pertinent issues (eg, cardiovascular pharmacology of triptans, epidemiology of cardiovascular disease, cardiovascular risk assessment, migraine) were presented as a prelude to group discussion and formulation of consensus conclusions and recommendations. Follow‐up meetings were held by telephone.
Conclusions.—(1) Most of the data on triptans are derived from patients without known coronary artery disease. (2) Chest symptoms occurring during use of triptans are generally nonserious and are not explained by ischemia. (3) The incidence of serious cardiovascular events with triptans in both clinical trials and clinical practice appears to be extremely low. (4) The cardiovascular risk‐benefit profile of triptans favors their use in the absence of contraindications.
Từ khóa
Tài liệu tham khảo
Matchar DB, 2000, Multispecialty consensus on diagnosis and treatment of headache: pharmacological management of acute attacks, Neurology, 54
Practice guidelines: official AAN practice statements. Available at:http://www.aan.com/public/practiceguidelines/list.htm. Accessed July 20 2002.
OlivaA.HFD‐120 FDA Medical Review of New Drug Application 21‐006;1999.
Sargent J, 1995, Oral sumatriptan is effective and well‐tolerated for the acute treatment of migraine: results of a multicenter study, Neurology, 45, S10
Adverse Event Reporting System. Data on file.2002.Available upon request from corresponding author D Dodick.
Zolmitriptan[prescribing information]. Wilmington DE :AstraZeneca;1999.
Rizatriptan[prescribing information]. Whitehouse Station NJ :Merck;1999.
Sumatriptan Tablets[prescribing information]. Research Triangle Park NC :GlaxoSmithKline;2001.
Naratriptan[prescribing information]. Research Triangle Park NC :GlaxoSmithKline;2001.
Almotriptan[prescribing information]. Pharmacia;2001.
Longmore J, 1997, Comparison of the vasoconstrictor properties of the 5‐HT1B/1D receptors agonists rizatriptan and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols, Funct Neurol, 12, 3
MacIntyre PD, 1992, The effect of i.v. sumatriptan, a selective 5‐HT1 receptor agonist, on central haemodynamics and the coronary circulation, Br J Clin Pharmacol, 34, 541
Leon‐Sotomayor LA, 1974, Cardiac migraine—report of twelve cases, Angiology, 9, 121